NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY).
Table 9. Cefuroxime Axetil Tablets (May be administered without regard to meals.)
aThe safety and effectiveness of cefuroxime axetil tablets administered for less than 10 days in patients with acute exacerbations of chronic bronchitis have not been established.
Population/Infection
Dosage
Duration(days)
Adolescents and Adults (13 years and older)
Pharyngitis/tonsillitis
250 mg twice daily
10
Acute bacterial maxillary sinusitis
250 mg twice daily
10
Acute bacterial exacerbations of chronic bronchitis
250 or 500 mg twice daily
10a
Secondary bacterial infections of acute bronchitis
250 or 500 mg twice daily
5 to 10
Uncomplicated skin and skin‑-structure infections
250 or 500 mg twice daily
10
Uncomplicated urinary tract infections
250 mg twice daily
7 to 10
Uncomplicated gonorrhea
1,000 mg once daily
single dose
Early Lyme disease
500 mg twice daily
20
Pediatric Patients (who can swallow tablets whole)
Acute otitis media
250 mg twice daily
10
Acute bacterial maxillary sinusitis
250 mg twice daily
10
Patients With Renal Impairment
Because cefuroxime is eliminated primarily by the kidney, a dosage interval adjustment is required for patients whose creatinine clearance is <30 mL/min, as listed in Table 11.
Table 11. Dosing in Patients with Renal Impairment
Creatinine Clearance (mL/min)
Recommended Dosage
≥30
No dosage adjustment
10 to <30
Standard individual dose given every 24 hours
<10 (without hemodialysis)
Standard individual dose given every 48 hours
Hemodialysis
A single additional standard dose should be given at the end of each dialysis